

Psychopharmacologic Drugs Advisory Committee Meeting
The Great Room, White Oak Conference Center, Food and Drug Administration Campus
Silver Spring, Maryland
September 16, 2010

Meeting Roster

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Michael Y. Hwang, M.D.

Associate Professor of Psychiatry
Robert Wood Johnson Medical School
University of Medicine and Dentistry
of New Jersey (UMDNJ)
Serious Mental Illness Program Manager
Montrose, New York

Tonya Jo Hanson White, M.D.

Assistant Professor
Department of Child and Adolescent Psychiatry
Afdelings Kinder- en Jeugdpsychiatrie
Erasmus Medical Centre - Sophia
Rotterdam, Netherlands

Robert F. Woolson, Ph.D.

Professor Emeritus of Biostatistics
Medical University of South Carolina
Charleston, South Carolina
and University of Iowa
Iowa City, Iowa
Adjunct Professor
Department of Biostatistics & Bioinformatics
Duke University
Durham, North Carolina

TEMPORARY MEMBERS (Voting)

Louis E. Baxter, Sr., M.D., FASAM

Executive Medical Director
Professional Assistance Program of
New Jersey, Inc.
Princeton, New Jersey

Edward Covington, M.D.

Director, Neurological Center for Pain
Neurological Institute
Cleveland Clinic Foundation
Cleveland, Ohio

Jane C. Maxwell, Ph.D.

Senior Research Scientist
Addiction Research Institute
The University of Texas at Austin
Austin, Texas

Edward Michna, M.D., J.D.

Director, Pain Trial Center
Department of Anesthesia, Brigham and Women's
Hospital, Harvard Medical School
Boston, Massachusetts

Richard Denisco, M.D., M.P.H.

Medical Officer
Division of Epidemiology, Services and Prevention
Research (DESPR)
National Institute on Drug Abuse (NIDA)
National Institutes of Health
Bethesda, Maryland

Iván D. Montoya, M.D., M.P.H.

Acting Deputy Director
Division of Pharmacotherapies and Medical
Consequences (DPMC) of Drug Abuse
National Institute on Drug Abuse (NIDA)
National Institutes of Health
Bethesda, Maryland

Psychopharmacologic Drugs Advisory Committee Meeting

Food and Drug Administration

White Oak Conference Center

Silver Spring, Maryland

September 16, 2010

Meeting Roster

-continued-

Rodney Mullins

(Consumer Representative)

National Director, Public Health Consultants
and Advocates
Duluth, Georgia

Chung-yui Betty Tai, Ph.D.

Director, Center for the Clinical Trials Network
National Institute on Drug Abuse
National Institutes of Health
Bethesda, Maryland

Susan K. Schultz, M.D. (Acting Chair)

Professor of Psychiatry
Department of Psychiatry, Geriatric Division
University of Iowa Carver College of Medicine
Iowa City, Iowa

Michael Yesenko

(Patient Representative)
Rockville, Maryland

Sharon L. Walsh, Ph.D.

Professor, Department of Behavioral Science
Professor, Department of Psychiatry
Director, Center on Drug and Alcohol Research
University of Kentucky
Lexington, Kentucky

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

William Z. Potter, M.D., Ph.D.

(Industry Representative)

Philadelphia, Pennsylvania

FDA PARTICIPANTS (Non-Voting)

Curtis Rosebraugh, M.D.

Director, Office of Drug Evaluation
(ODE) II, Office of New Drugs (OND)
CDER, FDA

Bob Rappaport, M.D.

Director, Division of Anesthesia and
Analgesia Products (DAAP), ODE II, OND
CDER, FDA

Celia Winchell, M.D.

Clinical Team Leader, DAAP, ODE II, OND
CDER, FDA

Rigoberto Roca, M.D.

Medical Officer, DAAP, ODE II, OND
CDER, FDA

Robert O'Neill, M.D.

Director, Office of Biostatistics
Office of Translational Sciences
CDER, FDA